The Intellectual Property and Science business of Thomson Reuters, a leading provider of intelligent information for businesses and professionals, announced that Cortellis Clinical Trials Intelligence, its global clinical-drug-trial intelligence database, marked an industry-first milestone with the documentation of more than 180,000 clinical trials.
The database is designed to provide pharmaceutical professionals with greater and quicker access to critical data and strategic insights to build stronger, more effective clinical trials. Launched in August 2013, it is part of the Cortellis suite, a source of life sciences intelligence information and analytics across multiple disciplines including regulatory, business development, discovery and pre-clinical.
Thomson Reuters' Cortellis Clinical Trials Intelligence gives life science professionals access to information and analytics from more than 180,000 global clinical trials, including coverage of drugs, biologics, diagnostics, biomarkers and medical devices, supporting a wide range of outcome searching. Cortellis users can gain deeper scientific and competitive insights by connecting clinical trial data with drug pipelines, patents, pre-clinical insights and biomarkers on a single, unified platform, reducing time spent compiling and analyzing clinical information, and to ultimately construct better trials. The information can also be accessed through APIs embedded in a customer's existing workflow or third-party software applications.
"We are proud to have reached this significant industry milestone within the first year of releasing Cortellis Clinical Trials Intelligence," said Jon Brett-Harris, managing director, Thomson Reuters IP & Science. "This rapid development is a reflection of our continued commitment to provide the best available information to support the pharmaceutical industry in driving successful clinical trials."
Cortellis Clinical Trial Intelligence makes program planning and competitive research simpler and more efficient as the number of clinical trials in the database continues to grow. The solution also allows users to discover competitor strategies for specific patient segments, biomarker utilization, end points and novel insights into disease processes and to uncover vital connections by integrating their internal, proprietary data with the wide variety of reference information available through Cortellis.
Thomson Reuters is a leading source of intelligent information for businesses and professionals. The company combines industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by a long-established's most trusted news organization.